+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of recombinant human granulocyte colony-stimulating factor (G-CSF) in the treatment of Pseudomonas aeruginosa bacteremia complicating hematologic malignancy--a preliminary study



Effect of recombinant human granulocyte colony-stimulating factor (G-CSF) in the treatment of Pseudomonas aeruginosa bacteremia complicating hematologic malignancy--a preliminary study



Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 66(1): 76-80



The efficacy of recombinant human granulocyte colony-stimulating factor (G-CSF) in the treatment of Pseudomonas aeruginosa bacteremia in cancer patients receiving intensive chemotherapy was studied retrospectively. In 14 of the 24 episodes of P. aeruginosa bacteremia, which occurred in 23 severely neutropenic patients with hematologic malignancies during a three-year period, G-CSF was given subcutaneously or intravenously at daily doses of 75 micrograms/body to 200 micrograms/m2 of body surface. Overall, survival at one week after onset was observed in 13 patients (54%). Treatment with G-CSF, however, had no statistically significant association with one-week survival, although a favorable outcome was well correlated with an increase in the neutrophil count during therapy. On the other hand, septic shock and appropriate antibiotic therapy were the major prognostic factors. The frequency of shock was reduced by appropriate therapy, but not by G-CSF treatment. These preliminary findings thus suggested that G-CSF should not be effective in the treatment of neutropenic cancer patients with P. aeruginosa bacteremia. No adverse effects of G-CSF were observed.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 039938642

Download citation: RISBibTeXText

PMID: 1383355


Related references

Successful treatment of breakthrough bacteremia due to Pseudomonas aeruginosa with recombinant human granulocyte colony-stimulating factor in a patient with acute leukemia. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 65(5): 608-611, 1991

Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood 74(8): 2644-2651, 1989

Effect of delayed treatment with recombinant human granulocyte colony-stimulating factor on survival and plasma cytokine levels in a non-neutropenic porcine model of Pseudomonas aeruginosa sepsis. Shock 9(2): 128-134, 1998

Hematologic effects of recombinant human granulocyte macrophage colony stimulating factor and interleukin-6 administered to patients with malignancy. Blood 84(10 Suppl. 1): 598A, 1994

Neutropenia complicating Rh-hydrops fetalis: the effect of treatment with recombinant human granulocyte colony-stimulating factor (rhG-CSF). Pediatric Hematology and Oncology 15(2): 193-197, 1998

Comparison of recombinant granulocyte colony-stimulating factor, recombinant human granulocyte-macrophage colony-stimulating factor and placebo for treatment of septic preterm infants. Pediatric Infectious Disease Journal 21(11): 1061-1065, 2002

Protective effect of recombinant murine granulocyte-macrophage colony-stimulating factor against Pseudomonas aeruginosa infection in leukocytopenic mice. Infection and Immunity 57(6): 1792-1799, 1989

The effect of three human recombinant hematopoietic growth factors (granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, and interleukin-3) on phagocyte oxidative activity. Blood 81(7): 1863-1870, 1993

Enhanced Effect of Mutant Granulocyte-Colony-Stimulating Factor (Kw-2228) on the Growth of Normal and Leukemic Hemopoietic Progenitor Cells in Comparison with Recombinant Human Granulocyte-Colony-Stimulating Factor (G-Csf). Acta Haematologica 87(4): 181-189, 1992

Enhanced effect of mutant granulocyte-colony-stimulating factor (KW-2228) on the growth of normal and leukemic hemopoietic progenitor cells in comparison with recombinant human granulocyte-colony-stimulating factor (G-CSF). Acta Haematologica 87(4): 181-189, 1992

Effect of human recombinant granulocyte/macrophage colony-stimulating factor and native granulocyte colony-stimulating factor on clonogenic leukemic blast cells. Cancer Research 47(21): 5647-5648, 1987

Studies of Drug Delivery Systems for Granulocyte Colony-Stimulating Factor (G-Csf). Part Iv. Pharmacodynamic Activity (Leukopoietic Effect) of Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-Csf) after Rectal Administration in Rabbits with Leukopenia Induced by Cyclophosphamide. Biological & Pharmaceutical Bulletin 19(8): 1064-1067, 1996

Effect of recombinant human interleukin 3, granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor on human BFU-e in serum-free cultures. International Journal of Cell Cloning 7(1): 39-49, 1989

Mechanism of protective effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on Pseudomonas infection. Microbiology and Immunology 35(6): 461-474, 1991

Effect of recombinant human granulocyte colony-stimulating factor on combination therapy with aztreonam and clindamycin for infections in neutropenic patients with hematologic diseases. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 70(12): 1242-1253, 1996